CordenPharma completes HPAPI laboratory expansion

Published: 19-Oct-2020
Manufacturing Finance Estates & Facilities

The laboratory is capable of handling highly potent compounds with an OEL as low as 1 ng/m3, and is already available to customers

CordenPharma has announced the completion of a highly potent API laboratory in its Boulder, Colorado facility.

CordenPharma says it has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. “Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.

  • Companies:
  • CordenPharma
See more

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

Read more
The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe
Manufacturing

Wacker and CordenPharma expand vaccine production capacity, enhancing ‘pandemic readiness’

The expansion follows an initiative the German government have launched to be 'pandemic ready', and boosts the duo's mRNA vaccine manufacturing capabilities
Manufacturing

CordenPharma and Certest partner to showcase the potential of ionisable lipids in LNP formulation

The agreement gives CordenPharma access to Certest's ionisable lipids platform, extending the company's ability to assist with the discovery, development and manufacturing of xRNA and xDNA
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Manufacturing

CordenPharma launches lipid nanoparticle starter kits

The kits will aid in loss mitigation of high-value payloads during the gene editing journey to market
Manufacturing

CPHI Barcelona Snapshot: CordenPharma

At CPHI Barcelona, Dr Kevin Robinson talked to Dr Michael Quirmbach, CEO and President of CordenPharma, about the company’s recent activities and what lies ahead
Subscribe now